Chest
Volume 130, Issue 4, Supplement, October 2006, Page 254S
Poster PresentationsPHARMACOKINETIC INTERACTION BETWEEN TADALAFIL AND BOSENTAN IN HEALTHY MALE SUBJECTS
Section snippets
Abstract
PURPOSE: Tadalafil is an oral phosphodiesterase type 5 (PDE5) inhibitor approved for the treatment of erectile dysfunction and under investigation for the once-daily treatment of pulmonary arterial hypertension (PAH). Since bosentan is an oral, dual endothelin receptor antagonist indicated in the treatment of patients with PAH, this study determined whether pharmacokinetic interactions exist between tadalafil and bosentan.
METHODS: This was an open-label, randomized, three-period crossover
References (0)
Cited by (0)
Copyright © 2006 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.